Lurbinectedin
Lurbinectedin (Zepzelca, Pharma Mar S.A.) has 1 EU-approved indication in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Small cell lung cancer1 | |||
None | + atezolizumab | Maint. advanced | After first-line induction therapy with atezolizumab, carboplatin and etoposide without disease progression |
Full text of section 4.1 (therapeutic indications)
ZEPZELCA, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
Label history
There is no record of changes to the Zepzelca label that oncolabels can read yet. EMA publishes it some months after the first approval.